← Back to Search

Hemophilia A patients for Hemophilia A (LIFE-ACTIVE Trial)

N/A
Waitlist Available
Research Sponsored by Bayer
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 30 days at each visit (baseline, year 1, 2 and 3)
Awards & highlights

LIFE-ACTIVE Trial Summary

In this study researcher want to learn more about the change of physical activity of hemophilia A patients treated with damoctocog alfa pegol. Patients enrolled in this study will be wearing a small device measuring daily active time. Researcher will compare these physical activity data with patient's clinical data including bleeding events to gain information on how bleeding levels are related to the activity level of the patients. The study aims to enroll about 80 patients who are at the same time also participating in the HEM-POWR study (NCT03932201) evaluating the effectiveness and safety of damoctocog alfa pegol.

LIFE-ACTIVE Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~30 days at each visit (baseline, year 1, 2 and 3)
This trial's timeline: 3 weeks for screening, Varies for treatment, and 30 days at each visit (baseline, year 1, 2 and 3) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Category of physical non-sedentary activity
Time of physical non-sedentary activity per week
Secondary outcome measures
Actual wear time per week
Association between physical activity time per week and PRO-scores for health-related life quality
Association between physical activity time per week and PRO-scores for treatment satisfaction
+11 more

Side effects data

From 2022 Phase 4 trial • 32 Patients • NCT04085458
16%
Upper respiratory tract infection
9%
Arthralgia
9%
Limb injury
6%
Tooth extraction
6%
Back pain
6%
Cough
6%
Epistaxis
6%
Pyrexia
3%
Fall
3%
Osteoarthritis
100%
80%
60%
40%
20%
0%
Study treatment Arm
Severe Hemophilia A Patients With Damoctocog Alfa Pegol (Jivi, BAY94-9027) Treatment

LIFE-ACTIVE Trial Design

1Treatment groups
Experimental Treatment
Group I: Hemophilia A patientsExperimental Treatment1 Intervention
Patients with hemophilia A who are being treated with Damoctocog alfa pegol (Jivi, BAY94-9027) in routine medical practice and are enrolled in Bayer-sponsored study NCT03932201
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Damoctocog alfa pegol (Jivi, BAY94-9027)
2019
Completed Phase 4
~40

Find a Location

Who is running the clinical trial?

BayerLead Sponsor
2,245 Previous Clinical Trials
25,333,184 Total Patients Enrolled
60 Trials studying Hemophilia A
5,632 Patients Enrolled for Hemophilia A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Study to Learn More About the Physical Activity Level of Patients Suffering From Hemophilia A Treated With Damoctocog Alfa Pegol (LIFE ACTIVE Study)
2021. "Study to Learn More About the Physical Activity Level of Patients Suffering From Hemophilia A Treated With Damoctocog Alfa Pegol (LIFE ACTIVE Study)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04091386.
~3 spots leftby Dec 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top